Kodiak Sciences Inc.
For the period ended Jun 2, 2025. Filed Apr 22, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 2, 2025 · Filed Apr 22, 2025
KOD$99.30+9.1%Stored close · as of Nov 6, 2026
Contents
Continuing Directors
Conti nuing Directors in Office Until the 2026 Annual Meeting of Stockholders
| Committees: •Audit (Chair)•Compensation•Nominating and Governance | Charles A. Bancroft |
|---|---|
| DirectorDirector since: 2020 Age: 65 | |
| BiographyCharles A. Bancroft has served as a member of our board of directors and as chair of our audit committee and a member of our nominating and governance committee since April 2020 and as a member of our compensation committee since April 2021. Prior to joining our company, Mr. Bancroft held a number of leadership roles in commercial, strategy and finance at Bristol-Myers Squibb Company, a global pharmaceutical company, from 1984 until his retirement in March 2020, including serving as the Chief Financial Officer from January 2010 to November 2019. Since May 2020, Mr. Bancroft has been serving as an independent director of GSK, a public pharmaceutical company. Since October 2020, Mr. Bancroft has been serving as an independent director of Biovector, Inc., a privately held healthcare company. Mr. Bancroft served as a member of the board of directors of Colgate-Palmolive Company, a public consumer products company, from January 2017 to March 2020. He holds a bachelor’s degree from Drexel University and a M.B.A. from Temple University. | Relevant ExpertiseWe believe Mr. Bancroft’s extensive management and financial experiences as well as his extensive involvement in the pharmaceutical industry qualify him to serve on our board of directors. Other Public Company BoardsGSK |
| 10 | 2025 PROXY STATEMENT |
Continuing Directors in Office Until the 2026 Annual Meeting of Stockholders
| Committees: •Audit | Bassil I. Dahiyat, Ph.D. |
|---|---|
| DirectorDirector since: 2018 Age: 54 | |
| BiographyBassil I. Dahiyat, Ph.D. has served as a member of our board of directors since June 2018 and as a member of our audit committee since September 2018. Dr. Dahiyat has served as President and Chief Executive Officer of Xencor, Inc., a biopharmaceutical company, since February 2005. Dr. Dahiyat co-founded Xencor in 1997, served as its Chief Executive Officer from 1997 to 2003 and served as its Chief Scientific Officer from 2003 to 2005. In 2005, Dr. Dahiyat was recognized as a technology pioneer by the World Economic Forum. Additionally, Dr. Dahiyat was named one of 2003’s Top 100 Young Innovators by MIT’s Technology Review magazine for his work on protein design and its development for therapeutic applications and has received awards from the American Chemical Society, the Controlled Release Society and the California Institute of Technology. Dr. Dahiyat currently serves on Xencor’s board of directors. Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University. | Relevant ExpertiseWe believe Dr. Dahiyat’s significant experience in the pharmaceutical industry and executive management experience qualify him to serve on our board of directors. Other Public Company BoardsXencor, Inc. |
| 2025 PROXY STATEMENT | 11 |
Continuing Directors in Office Until the 2026 Annual Meeting of Stockholders
| Committees: •Audit | Taiyin Yang, Ph.D. |
|---|---|
| DirectorDirector since: 2019 Age: 71 | |
| BiographyTaiyin Yang, Ph.D. has served as a member of our board of directors and a member of our audit committee since December 2019. Dr. Yang is the former Executive Vice President of Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc., a role she held from 2015 to 2022. She directed operations of chemical and biologics process development, device and formulation development, manufacturing, packaging, analytical operations, laboratory information systems, data science, quality assurance, CMC regulatory affairs, program management, supply chain management and site operations for all the company’s small molecules, biologics and antibody-drug conjugates of investigational compounds and marketed products. Under her leadership, Gilead developed the world’s first HIV single tablet regimen and advanced more than 25 compounds from early-stage development to market, reaching millions of people around the world. Prior to joining Gilead in 1993, Dr. Yang worked at Syntex Corporation from 1980 where she contributed to the development and commercialization of more than 10 medicines. Dr. Yang serves on the board of directors of Kronos Bio, Inc. since 2021 and Brii Biosciences since 2022. Dr. Yang was a member of the Expert Scientific Advisory Committee of Medicines for Malaria Venture from 2020 to 2023, and is a member of the scientific advisory board of Sionna Therapeutics since 2022. Dr. Yang received her bachelor’s degree in Chemistry from National Taiwan University and her Ph.D. in Organic Chemistry from the University of Southern California. Dr. Yang was inducted as a fellow of the American Institute for Medical and Biological Engineering in 2021 and elected a member of the National Academy of Engineering in 2022. | Relevant ExpertiseWe believe Dr. Yang’s extensive management experience and internationally recognized scientific expertise in the pharmaceutical industry qualify her to serve on our board of directors. Other Public Company BoardsKronos Bio, Inc.Brii Biosciences Limited |
| 12 | 2025 PROXY STATEMENT |
Continuing Directors in Office Until the 2027 Annual Meeting of Stockholders
| Committees: •Compensation (Chair)•Nominating and Governance | Felix J. Baker, Ph.D. |
|---|---|
| DirectorDirector since: 2015 Age: 56 | |
| BiographyFelix J. Baker, Ph.D. has served as one of our directors since September 2015 and as chair of our compensation committee and a member of our nominating and governance committee since September 2018. Dr. Baker is a Managing Member of Baker Bros. Advisors LP a biotechnology-focused investment adviser to fund partnerships whose investors are primarily endowments and foundations, which Dr. Baker founded, together with his brother Julian Baker, in 2000. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. He also serves on the boards of Kiniksa Pharmaceuticals International, plc., IGM Biosciences, Inc., Kymera Therapeutics, Inc., and Bicycle Therapeutics plc. Previously he served on the board of N-Power Medicine from September 2021 through December 2024, Seagen, Inc. from July 2003 through December 2023, Talis Biomedical Corporation from July 2013 through March 2023, and Alexion Pharmaceuticals, Inc. from June 2015 through February 2021. | Relevant ExpertiseWe believe Dr. Baker’s experience as a board member and investor in many successful biotechnology companies qualify him to serve on our board of directors. Other Public Company BoardsKiniksa Pharmaceuticals International, plc.IGM Biosciences, Inc.Kymera Therapeutics, Inc.Bicycle Therapeutics plc |
| 2025 PROXY STATEMENT | 13 |
Continuing Directors in Office Until the 2027 Annual Meeting of Stockholders
| Committees: •None | Victor Perlroth, M.D. |
|---|---|
| Chairman and Chief Executive OfficerDirector since: 2009 Age: 52 | |
| BiographyVictor Perlroth, M.D. is the co-founder of Kodiak Sciences and is the company’s chairman and chief executive officer. Together with a talented core team, Dr. Perlroth has built Kodiak on a foundation of scientific and operational excellence with a simple mission – to design and develop important new medicines for highly prevalent diseases. Under Dr. Perlroth’s leadership, Kodiak is building a pipeline of potentially life transforming ophthalmology drug candidates with the goal to build a leading retinal franchise for the benefit of patients globally. Prior to co-founding Kodiak, Dr. Perlroth co-founded Avidia Inc, a biopharmaceuticals drug discovery and development company where he served in senior corporate and research and development roles until Amgen acquired the company for $450 million. After Avidia, Dr. Perlroth worked in life sciences venture capital as venture partner then entrepreneur in residence. Earlier, Dr. Perlroth served as the chief operating officer at Guzik Technical Enterprises, the industry-leading provider of test equipment to the hard disk drive industry. Dr. Perlroth earned his M.D. and M.B.A. degrees from Stanford University and an A.B. in molecular biology summa cum laude from Princeton University. | Relevant ExpertiseWe believe the perspective and experience Dr. Perlroth brings to Kodiak as a founder, our largest individual stockholder and as our Chief Executive Officer allow him to provide unique contribution to the Board and qualify him to serve as a member of the Board. Other Public Company BoardsNone |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.